SCHEMBL30355649

SCHEMBL30355649

Cc1ccccc1-c1noc(-c2ccc3scnc3c2)n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.55
SMN1; SMN2 Q16637 5/20 0.55
RAB9A P51151 4/20 0.55
MAPT P10636 2/20 0.55
MEN1 O00255 1/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2C19 P33261 1/20 0.55
KMT2A Q03164 1/20 0.55
PKM P14618 1/20 0.55
NFKB1 P19838 1/20 0.55
NFKB2 Q00653 1/20 0.55
RELA Q04206 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
HSD17B10 Q99714 1/20 0.55
NR1H4 Q96RI1 3/20 0.53
MAPK1 P28482 2/20 0.53
GAA P10253 2/20 0.53
TP53 P04637 1/20 0.53
TDP1 Q9NUW8 1/20 0.51
S1PR1 P21453 9/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23524047 1.00 NPC1 (0.55) NPC1SMN1; SMN2RAB9AMAPTMEN1
SCHEMBL21508018 0.81 ALOX5AP (0.49) SMN1; SMN2CYP1A2CYP2C19NPSR1HSD17B10
SCHEMBL22628959 0.80 ACHE (0.47) MAPTTP53
SCHEMBL1421337 0.76 NPC1 (0.60) NPC1SMN1; SMN2RAB9AMAPTNFKB1
SCHEMBL21485722 0.74 NPC1 (0.77) NPC1SMN1; SMN2RAB9AMAPTMEN1
SCHEMBL25856644 0.72 NPC1 (0.51) NPC1SMN1; SMN2RAB9AMAPTMEN1
SCHEMBL13525245 0.72 NPC1 (0.80) NPC1SMN1; SMN2RAB9AMAPTMEN1
SCHEMBL21480513 0.72 SMN1; SMN2 (0.73) NPC1SMN1; SMN2RAB9AMAPTMEN1
SCHEMBL13416232 0.72 S1PR1 (0.82) NPC1SMN1; SMN2RAB9AHSD17B10MAPK1
SCHEMBL3746152 0.71 NPC1 (0.59) NPC1SMN1; SMN2RAB9AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912693-B2 Compounds for modulating S1P1 activity and methods of using the same TREVENA, INC. (US) 2024-02-27 US disclosed
US-20230234946-A1 COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME TREVENA, INC. 2023-07-27 US disclosed
US-20230114241-A1 METHODS OF TREATING EPILEPSY USING THE SAME TREVENA, INC. 2023-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234946-A1 COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME S1PR1, S1PR2, S1PR3 NPC1 301/4885SMN1; SMN2 1320/4885RAB9A 3056/4885
US-20230114241-A1 METHODS OF TREATING EPILEPSY USING THE SAME S1PR1, S1PR2, S1PR3 NPC1 311/4885SMN1; SMN2 619/4885RAB9A 2056/4885
US-11912693-B2 Compounds for modulating S1P1 activity and methods of using the same S1PR1, S1PR2, S1PR3 NPC1 301/4885SMN1; SMN2 1320/4885RAB9A 3056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.